Deciphera obtient l’autorisation de la commission européenne pour le QINLOCK® (RIPRETINIB) en traitement de quatrième ligne des tumeurs stromales gastro-intestinales (GIST)
Amolyt Pharma obtient la désignation de médicament orphelin de la FDA pour l’AZP-3601 pour le traitement potentiel de l’hypoparathyroïdie
Nosopharm obtains US patent for NOSO-502, a first-in-class novel antibiotic
Dianosic obtains CE marking for CAVI-T, medical device for treating intranasal bleeding
Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
